Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients

This study aimed to determine the clinical impact of CD25(+)/CD123(+) coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Aref, Salah, El Agdar, Mohamed, Khaled, Nada, Ibrahim, Lamyaa, El-Ghonemy, Mohamed S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256740/
https://www.ncbi.nlm.nih.gov/pubmed/32518561
http://dx.doi.org/10.1155/2020/9545717
Descripción
Sumario:This study aimed to determine the clinical impact of CD25(+)/CD123(+) coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study. CD123 and CD25 expression on leukemic blast cells were assessed using flow cytometry. CD25(+)/CD123(+) coexpression was detected in 40/120 B-ALL patients (33.3%). All B-ALL patients showed CD25(+)/CD123(+) coexpression had lower induction of remission response and shorter overall survival as compared to B-ALL cases lacking coexpression. In conclusion, CD25(+)/CD123(+) positive coexpression is a reliable flow cytometry marker for prediction of the outcome of adult B-ALL patients and could be used as a novel parameter for risk stratification of adult B-ALL cases.

Ejemplares similares